Share Name Share Symbol Market Type Share ISIN Share Description
Indivior LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +4.40p +1.12% 397.40p 396.30p 396.80p 399.40p 392.40p 395.50p 1,582,728 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 688.2 193.4 21.7 16.5 2,865.21

Indivior (INDV) Latest News

More Indivior News
Indivior Takeover Rumours

Indivior (INDV) Share Charts

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart

Intraday Indivior Chart

Intraday Indivior Chart

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
12/12/201710:47RB. de-merger 354
02/12/201711:15INDIVIOR THE PILL WITH NO CHEERS OR BEERS12
25/9/201707:32INDIVIOR3

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:10:08397.4057,873229,987.30O
17:02:30395.746,73526,653.08O
17:02:08396.5214,75158,490.00O
16:54:25395.943,94615,623.82O
16:53:22397.4014,02555,735.35O
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

DateSubject
18/12/2017
08:20
Indivior Daily Update: Indivior is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 393p.
Indivior has a 4 week average price of 359.30p and a 12 week average price of 322.40p.
The 1 year high share price is 421.50p while the 1 year low share price is currently 246.50p.
There are currently 720,988,383 shares in issue and the average daily traded volume is 2,106,452 shares. The market capitalisation of Indivior is £2,865,207,834.04.
01/11/2017
11:47
gregmorg: Yup, as you say, who knows with this one! Good thing is it is increasingly looking a less dangerous/more secure company. So after the 2nd November we then roll on to that other tester of our investors steel --on the 14th. Will see how that coding scenario has developed . It could be the stock starts to put the days of serious uncertainty behind it. Revenues are looking good and growing very respectably. But what about the veins!~! Thinking of patience(or apathy!) I have been a little puzzled by GSK's share price performance in recent time but am hoping this baptism of fire gears up/fires up the new CEO. OR what! As for my other pharma, IMB, I do wish, Steeplejack, I had more noted your disposal some months back and so questioned my own rationale. Good call. Now I am left waiting for Vaping to kick in! Hopefully this is made less painless by a continued good stream of dividends. Let's see what tomorrow brings on IND . Unfortunately I cannot listen in to the live investors meeting as I have some silly cross country trail commitment. Hopefully I can listen in later in the day.
31/10/2017
21:06
gregmorg: Steeplejack. I understand the Committee vote at the end was 18 for and one against.The latter was on the basis of this was nothing new! This, I hasten to add, is purely my understanding. I did say this Committee is advisory but it does look as if the recommendation to the FDA is going our way. A few concerns were raised re the results of the 300mg doses( as opposed to the 100mg) and a few small issues that resulted, but this does not appear to have affected the outcome. So possibly it is looking OK!. We both have experiences of erratic share price performance across the financial reporting period so its important to maintain the longer view.
04/8/2016
17:47
gregmorg: Finally, days too late of course, I fully read the interim statement and listened to the webcast, including questions and answers. If I may say so Steeplejack, I think your investing stance remains sound! Actually, I wouldn't mind a bit of share price weakness for purely simple/ greedy reasons. We could get that with so many big items on the horizon between now and November although there are further presentations in the Autumn which may or may not counter. From my perspective it was a good and illuminating presentation
07/7/2016
15:38
gregmorg: Yes, nice to see. As far as I am concerned ,once again, inertia is a wonderful investment strategy! I thought the recent executive(chief legal officer) buying was encouraging. He must believe the recent patent win was good for a positive resolution of the other patent disputes. Some have argued that the share price strength is as a result of sterling's weakness for this dollar earner but at this stage of its development I don't buy that.
16/6/2016
14:40
gregmorg: Yup. Nice to see. I thought the Jefferies presentation on 7th June, four days after the posiive patent decision was very upbeat.Talking of removing uncertainties to the business plus Bup Monthly Depot being a game changer(potentially that is!). More news on the latter, of course, coming in the third qtr. I liked the presentation with the management sounding in very positive mood. Share price moves in recent days may have reflected some of this uptick in mood although its a guess as, other than this stab in the dark, I havent a clue. Taken the view nothing reflects vaue currently and just will see what the next few weeks bring on all stocks.
07/6/2016
08:40
gregmorg: Makes sense. Mind you, in terms of share price movement.The usual consensus is that a third give back after a significant share price rise is healthy! Steeplejack you mentio Merrills change of investment stance but purely for my edification can you say what their public stance was beforehand please? i was very happy to see that last piece of patent news so feel the longer term investment view remains intact.Essentially am sitting tight and awaiting events.
07/6/2016
06:53
steeplejack: Artemis have sold some 0.46% of their equity holding,around 3 million shares to take their holding to 4.68%. Today's FT market report carries a fairly long review of yesterday's share price fall.Merrill has moved to a neutral rating while RBC also warns that the Delaware ruling is not the end of the matter,another generic competitor hearing is upcoming this November and at the end of the day,the success of the injectible version,which Indivior is to launch in the second half of 2017,remains paramount. So sobering stuff after Friday's euphoria.Yet,it's easy to feel that the Delaware judgement buys Indivior some time.
12/5/2016
12:58
gregmorg: I didn't bother attending the AGM today as its location somewhere near Heathrow on the Bath Road said it all! Obviously the location was chosen to fit in with the executives busy travel schedules and with every expectation that no shareholders or even representative from institutional investors were likely to turn up. These locations get chosen to highlight the point that nothing of interest is likely to be said and its all just a matter of regulatory form. Still the share price has recovered a tad from its wobbles although I guess we wait till some Court judgements or other drug news.
18/2/2016
13:36
gregmorg: Yes, I too wondered about the weak share price. Companies do visit major share holders and discuss strategy and other mostly non price sensitive areas. With such an important decision-it would be strange not to have sounded out the major investors. That can make them insiders which puts the stock on a restricted list for that investment house. A side effect can be that if you had the stock on your buy list then they stop buying the stock--plus,of course, they cannot sell! Compliance chaps are very strict about these thing. The result can be the buyers get stopped from buying yet the natural flow of sellers keep on. So sometimes the share price can reflect an issue without the market fully realizing it. I listened to the webcast but missed out on the questions and answers because the transmission went wonky. Takes time to form a view of this one, so in time honored fashion, I am contemplating my navel for a few weeks while trying to digest!
05/12/2015
11:12
gregmorg: The share sales position has been very confusing with the legacy JAB disposal technically taking place between 9th Nov and 30 Nov. so no announcement in that period! My understanding is the institution which took the stake covered it with a series of complex hedging arrangements presumably allowing them to place their stock/or much of it, in the market with the minimum of fuss/publicity. The JAB disposal took time to soak up possibly weakening the share price over a period .Even 9th November could be a false start date as positions would have been taken well before then. So we could have some explanation for the share price performance since the summer! Actually I am less concerned with the recent term share price performance but more concerned with the longer term development of the product and revenue base. The Co's research and teach in date of 9 Dec is hopefully a significant event rather than one buying time. Not long to wait.
Indivior share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171218 18:14:10